The building blocks of successful translation of proteomics to the clinic

•Blood is a window into the health state of the body.•The first two multiplexed blood protein tests using selective reaction monitoring mass spectrometry (SRM-MS) have now entered clinical practice.•Development of both tests used the same strategy from discovery through clinical use.•This strategy s...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in biotechnology 2018-06, Vol.51, p.123-129
Main Authors: Kearney, Paul, Boniface, J Jay, Price, Nathan D, Hood, Leroy
Format: Article
Language:English
Subjects:
biomarkers
Biomarkers - analysis
blood proteins
Blood Proteins - analysis
Humans
lung neoplasms
mass spectrometry
monitoring
Neoplasms - blood
Neoplasms - diagnosis
phenotype
Precision Medicine
premature birth
proteomics
Proteomics - methods
risk assessment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Blood is a window into the health state of the body.•The first two multiplexed blood protein tests using selective reaction monitoring mass spectrometry (SRM-MS) have now entered clinical practice.•Development of both tests used the same strategy from discovery through clinical use.•This strategy succeeded in two different applications: lung cancer and pre-term birth.•We present here that strategy as a roadmap for development of future tests for other indications. [Display omitted] •Many omics-based tests are proposed in the literature but very few make it to the clinic.•First two multiplexed tests using selective reaction monitoring (SRM-MS) mass spectrometry in the blood have entered clinical practice.•Development of both tests used the same strategy from discovery through clinical use.•This strategy succeeded in two different applications: lung cancer and pre-term birth.•We present here that strategy as a roadmap for development of future tests for other indications. Recently, the first two multiplexed tests using selective reaction monitoring (SRM-MS) mass spectrometry have entered clinical practice. Despite different areas of indication, risk stratification in lung cancer and preterm birth, they share multiple steps in their development strategies. Here we review these strategies and their implications for successful translation of biomarkers to clinical practice. We believe that the identification of blood protein panels for the identification of disease phenotypes is now a reproducible and standard (albeit complex) process.
ISSN:0958-1669
1879-0429
1879-0429
DOI:10.1016/j.copbio.2017.12.011